According to Sina Finance, the European Commission has approved Sanofi’s VaxRabeo rabies vaccine for people of all ages, for both pre-exposure and post-exposure prevention. Sanofi announced the approval on November 19, marking the vaccine’s first marketing authorization anywhere in the world.

VaxRabeo uses Vero cell technology and is designed to reduce the risk of allergic reactions. Compared with Sanofi’s existing rabies vaccines, Verorab and Imovax Rabies, it has a shelf life of up to five years and can remain stable for 96 hours at temperatures up to 27°C before reconstitution.

The approval was based on comparative clinical studies covering all age groups and using pre-exposure and post-exposure vaccination schedules recommended by the World Health Organization. VaxRabeo produced protective antibody levels comparable to the existing vaccines and showed a good immune response to booster doses given 12 months after the initial vaccination or 24 to 36 months afterward.

The World Health Organization estimates that rabies is present in about 150 countries, causes about 59,000 deaths annually, and leads roughly 29 million people to receive post-exposure vaccination. The disease is mainly transmitted through the saliva of infected animals. Once symptoms appear, the fatality rate is nearly 100%, but timely vaccination can prevent the disease.